{"transactions":[{"id":671075,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17930,"kind":"person","name":"Kalofonos Isabel","position":1,"cik":"0001975163","reported_name":"Kalofonos Isabel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-01T20:55:10.000Z","date":"2026-09-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":55000,"price":41.21,"value":2266550.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a \"Company Stock Option\").  Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a \"Company Stock Option\").  Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options."}],"balance_after":0,"derivative":{"exercise_price":43.79,"expiration_date":"2036-02-23","underlying":"Common Stock","underlying_shares":55000},"source":{"system":"sec-edgar","filing":"0001628280-26-059885","document":"wk-form4_1788296108.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000162828026059885/wk-form4_1788296108.xml","form_type":"4"}},{"id":671074,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17930,"kind":"person","name":"Kalofonos Isabel","position":1,"cik":"0001975163","reported_name":"Kalofonos Isabel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-01T20:55:10.000Z","date":"2026-09-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":97500,"price":44.41,"value":4329975.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a \"Company Stock Option\").  Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a \"Company Stock Option\").  Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options."}],"balance_after":0,"derivative":{"exercise_price":40.59,"expiration_date":"2035-01-10","underlying":"Common Stock","underlying_shares":97500},"source":{"system":"sec-edgar","filing":"0001628280-26-059885","document":"wk-form4_1788296108.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000162828026059885/wk-form4_1788296108.xml","form_type":"4"}},{"id":671073,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17930,"kind":"person","name":"Kalofonos Isabel","position":1,"cik":"0001975163","reported_name":"Kalofonos Isabel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2026-09-01T20:55:10.000Z","date":"2026-09-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":34000,"price":85,"value":2890000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transaction reported on this line reflects the cancellation in the Merger of restricted stock units of the Company (each, a \"Company RSU\"), each of which represented a contingent right to receive one share of the Issuer's Common Stock. Immediately prior to the Effective Time, each Company RSU that was then outstanding but not vested became immediately vested in full. At the Effective Time, each outstanding Company RSU was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration, less any applicable tax withholding."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001628280-26-059885","document":"wk-form4_1788296108.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000162828026059885/wk-form4_1788296108.xml","form_type":"4"}},{"id":671072,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17930,"kind":"person","name":"Kalofonos Isabel","position":1,"cik":"0001975163","reported_name":"Kalofonos Isabel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2026-09-01T20:55:10.000Z","date":"2026-09-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1669,"price":85,"value":141865.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Includes 835 shares acquired under the Issuer's Employee Stock Purchase Plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Agreement and Plan of Merger, dated as of July 6, 2026 (the \"Merger Agreement\"), by and among Crinetics Pharmaceuticals, Inc., a Delaware corporation (the \"Company\"), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (\"Parent\"), and Clark Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), Merger Sub merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the \"Merger\"), effective as of September 1, 2026 (the \"Effective Time\"). At the Effective Time, each share of common stock of the Company, par value $0.001 per share (the \"Company Common Stock\"), issued and outstanding immediately prior to the Effective Time, except as provided in the Merger Agreement, was canceled and automatically converted into the right to receive $85.00 per share in cash, without interest and subject to any applicable tax withholdings (the \"Merger Consideration\")."}],"balance_after":34000,"source":{"system":"sec-edgar","filing":"0001628280-26-059885","document":"wk-form4_1788296108.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000162828026059885/wk-form4_1788296108.xml","form_type":"4"}},{"id":881973,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17930,"kind":"person","name":"Kalofonos Isabel","position":1,"cik":"0001975163","reported_name":"Kalofonos Isabel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-25T21:32:40.000Z","date":"2026-02-23","kind":"grant","planned":false,"acquired":true,"shares":55000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement date of February 23, 2026."}],"balance_after":55000,"derivative":{"exercise_price":43.79,"expiration_date":"2036-02-23","underlying":"Common Stock","underlying_shares":55000},"source":{"system":"sec-edgar","filing":"0001628280-26-011715","document":"wk-form4_1772055157.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000162828026011715/wk-form4_1772055157.xml","form_type":"4"}},{"id":881972,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17930,"kind":"person","name":"Kalofonos Isabel","position":1,"cik":"0001975163","reported_name":"Kalofonos Isabel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2026-02-25T21:32:40.000Z","date":"2026-02-23","kind":"grant","planned":false,"acquired":true,"shares":34000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 25% vesting annually beginning on March 1, 2027."}],"balance_after":34834,"source":{"system":"sec-edgar","filing":"0001628280-26-011715","document":"wk-form4_1772055157.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000162828026011715/wk-form4_1772055157.xml","form_type":"4"}},{"id":944493,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17930,"kind":"person","name":"Kalofonos Isabel","position":1,"cik":"0001975163","reported_name":"Kalofonos Isabel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-07T22:11:26.000Z","date":"2026-01-05","kind":"exercise","planned":true,"acquired":false,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option is exercisable as follows: 25% of the shares subject to the option vested on December 16, 2025, and the remaining number of shares subject to the option vest monthly thereafter in thirty-six equal monthly installments, subject to the Reporting Person's continued employment with the Issuer on each such vesting date."}],"balance_after":97500,"derivative":{"exercise_price":40.59,"expiration_date":"2035-01-10","underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0001628280-26-001230","document":"wk-form4_1767823884.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000162828026001230/wk-form4_1767823884.xml","form_type":"4"}},{"id":944492,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17930,"kind":"person","name":"Kalofonos Isabel","position":1,"cik":"0001975163","reported_name":"Kalofonos Isabel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2026-01-07T22:11:26.000Z","date":"2026-01-05","kind":"sale","planned":true,"acquired":false,"shares":2500,"price":55,"value":137500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 7, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The common stock was sold by the Reporting Person in an open market transaction on the transaction date, at a sale price of $55.00 per share."}],"balance_after":834,"source":{"system":"sec-edgar","filing":"0001628280-26-001230","document":"wk-form4_1767823884.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000162828026001230/wk-form4_1767823884.xml","form_type":"4"}},{"id":944491,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17930,"kind":"person","name":"Kalofonos Isabel","position":1,"cik":"0001975163","reported_name":"Kalofonos Isabel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2026-01-07T22:11:26.000Z","date":"2026-01-05","kind":"exercise","planned":true,"acquired":true,"shares":2500,"price":40.59,"value":101475.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 834 shares acquired under the Issuer's Employee Stock Purchase Plan."}],"balance_after":3334,"source":{"system":"sec-edgar","filing":"0001628280-26-001230","document":"wk-form4_1767823884.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000162828026001230/wk-form4_1767823884.xml","form_type":"4"}},{"id":1304308,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17930,"kind":"person","name":"Kalofonos Isabel","position":1,"cik":"0001975163","reported_name":"Kalofonos Isabel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-13T21:30:06.000Z","date":"2025-01-10","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option is exercisable as follows: 25% of the shares subject to the option vest on December 16, 2025, and the remaining number of shares subject to the option vest monthly thereafter in thirty-six equal monthly installments, subject to the Reporting Person's continued employment with the Issuer on each such vesting date."}],"balance_after":100000,"derivative":{"exercise_price":40.59,"expiration_date":"2035-01-09","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0000950170-25-004855","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000095017025004855/ownership.xml","form_type":"4"}},{"id":1650381,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":17930,"kind":"person","name":"Kalofonos Isabel","position":1,"cik":"0001975163","reported_name":"Kalofonos Isabel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & CHIEF COMMERCIAL OFFICER"}}],"security":"Restricted Stock Unit","published_at":"2024-02-12T16:38:17.000Z","date":"2024-02-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":19458,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each RSU granted on or after the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was converted into a grant of restricted stock unit awards in respect of a number of shares of AbbVie common stock equal to the number of shares of Common Stock underlying such RSU as of immediately prior to the Effective Time multiplied by 0.18, and otherwise with the same terms and conditions that were applicable immediately prior to the Effective Time."},{"field":"kind","element":"transactionCoding","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each RSU granted on or after the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was converted into a grant of restricted stock unit awards in respect of a number of shares of AbbVie common stock equal to the number of shares of Common Stock underlying such RSU as of immediately prior to the Effective Time multiplied by 0.18, and otherwise with the same terms and conditions that were applicable immediately prior to the Effective Time."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each RSU granted on or after the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was converted into a grant of restricted stock unit awards in respect of a number of shares of AbbVie common stock equal to the number of shares of Common Stock underlying such RSU as of immediately prior to the Effective Time multiplied by 0.18, and otherwise with the same terms and conditions that were applicable immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each RSU granted on or after the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was converted into a grant of restricted stock unit awards in respect of a number of shares of AbbVie common stock equal to the number of shares of Common Stock underlying such RSU as of immediately prior to the Effective Time multiplied by 0.18, and otherwise with the same terms and conditions that were applicable immediately prior to the Effective Time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each RSU granted on or after the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was converted into a grant of restricted stock unit awards in respect of a number of shares of AbbVie common stock equal to the number of shares of Common Stock underlying such RSU as of immediately prior to the Effective Time multiplied by 0.18, and otherwise with the same terms and conditions that were applicable immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":19458},"source":{"system":"sec-edgar","filing":"0001104659-24-014700","document":"tm245865-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/855654/000110465924014700/tm245865-4_4seq1.xml","form_type":"4"}},{"id":1650380,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":17930,"kind":"person","name":"Kalofonos Isabel","position":1,"cik":"0001975163","reported_name":"Kalofonos Isabel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & CHIEF COMMERCIAL OFFICER"}}],"security":"Restricted Stock Unit","published_at":"2024-02-12T16:38:17.000Z","date":"2024-02-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":47375,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit (\"RSU\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such RSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit (\"RSU\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such RSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit (\"RSU\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such RSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit (\"RSU\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such RSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit (\"RSU\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such RSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":47375},"source":{"system":"sec-edgar","filing":"0001104659-24-014700","document":"tm245865-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/855654/000110465924014700/tm245865-4_4seq1.xml","form_type":"4"}},{"id":1650379,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":17930,"kind":"person","name":"Kalofonos Isabel","position":1,"cik":"0001975163","reported_name":"Kalofonos Isabel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & CHIEF COMMERCIAL OFFICER"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-12T16:38:17.000Z","date":"2024-02-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":284250,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated November 30, 2023, by and among the Issuer, AbbVie Inc., a Delaware corporation (\"AbbVie\"), Athene Subsidiary LLC, a Delaware limited liability company and wholly owned subsidiary of AbbVie (\"Intermediate Sub\"), and Athene Merger Sub Inc., a Massachusetts corporation and wholly owned subsidiary of Intermediate Sub (\"Purchaser\"), pursuant to which Purchaser merged with and into the Issuer with the Issuer continuing as the surviving corporation (the \"Merger\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"At the effective time of the Merger (the \"Effective Time\"), each option to purchase shares of common stock, par value $.01 per share, of the Issuer (\"Common Stock,\" and such option, a \"Stock Option\") granted prior to the date of the Merger Agreement outstanding immediately prior to the Effective Time was canceled and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of $31.26, without interest (the \"Merger Consideration\"), over the applicable exercise price per share of Common Stock under such Stock Option."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated November 30, 2023, by and among the Issuer, AbbVie Inc., a Delaware corporation (\"AbbVie\"), Athene Subsidiary LLC, a Delaware limited liability company and wholly owned subsidiary of AbbVie (\"Intermediate Sub\"), and Athene Merger Sub Inc., a Massachusetts corporation and wholly owned subsidiary of Intermediate Sub (\"Purchaser\"), pursuant to which Purchaser merged with and into the Issuer with the Issuer continuing as the surviving corporation (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the effective time of the Merger (the \"Effective Time\"), each option to purchase shares of common stock, par value $.01 per share, of the Issuer (\"Common Stock,\" and such option, a \"Stock Option\") granted prior to the date of the Merger Agreement outstanding immediately prior to the Effective Time was canceled and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of $31.26, without interest (the \"Merger Consideration\"), over the applicable exercise price per share of Common Stock under such Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated November 30, 2023, by and among the Issuer, AbbVie Inc., a Delaware corporation (\"AbbVie\"), Athene Subsidiary LLC, a Delaware limited liability company and wholly owned subsidiary of AbbVie (\"Intermediate Sub\"), and Athene Merger Sub Inc., a Massachusetts corporation and wholly owned subsidiary of Intermediate Sub (\"Purchaser\"), pursuant to which Purchaser merged with and into the Issuer with the Issuer continuing as the surviving corporation (the \"Merger\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"At the effective time of the Merger (the \"Effective Time\"), each option to purchase shares of common stock, par value $.01 per share, of the Issuer (\"Common Stock,\" and such option, a \"Stock Option\") granted prior to the date of the Merger Agreement outstanding immediately prior to the Effective Time was canceled and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of $31.26, without interest (the \"Merger Consideration\"), over the applicable exercise price per share of Common Stock under such Stock Option."}],"balance_after":0,"derivative":{"exercise_price":5.39,"expiration_date":"2033-04-28","underlying":"Common Stock","underlying_shares":284250},"source":{"system":"sec-edgar","filing":"0001104659-24-014700","document":"tm245865-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/855654/000110465924014700/tm245865-4_4seq1.xml","form_type":"4"}},{"id":1659956,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":17930,"kind":"person","name":"Kalofonos Isabel","position":1,"cik":"0001975163","reported_name":"Kalofonos Isabel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & CHIEF COMMERCIAL OFFICER"}}],"security":"Restricted Stock Unit","published_at":"2024-02-05T21:30:30.000Z","date":"2024-02-01","kind":"grant","planned":false,"acquired":true,"shares":19458,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs vest over a three-year period, with 33 1/3% of the RSUs vesting on each of the first three anniversaries of the date of grant, subject to continued service through each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs vest over a three-year period, with 33 1/3% of the RSUs vesting on each of the first three anniversaries of the date of grant, subject to continued service through each vesting date."}],"balance_after":19458,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":19458},"source":{"system":"sec-edgar","filing":"0001415889-24-002765","document":"form4-02062024_020218.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/855654/000141588924002765/form4-02062024_020218.xml","form_type":"4"}},{"id":1909217,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":17930,"kind":"person","name":"Kalofonos Isabel","position":1,"cik":"0001975163","reported_name":"Kalofonos Isabel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & CHIEF COMMERCIAL OFFICER"}}],"security":"Restricted Stock Unit","published_at":"2023-05-02T16:32:00.000Z","date":"2023-04-28","kind":"grant","planned":false,"acquired":true,"shares":47375,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit (\"RSU\") represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These options vest over a four-year period, with 25% of the shares vesting on the one-year anniversary of the date of grant, and thereafter an additional 6.25% of the shares vesting on each succeeding quarterly anniversary of the date of grant, subject to continued service through each vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs vest over a four-year period, with 25% of the RSUs vesting on each of the first four anniversaries of the date of grant, subject to continued service through each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each restricted stock unit (\"RSU\") represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock."}],"balance_after":47375,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":47375},"source":{"system":"sec-edgar","filing":"0001415889-23-007094","document":"form4-05022023_080554.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/855654/000141588923007094/form4-05022023_080554.xml","form_type":"4"}},{"id":1909216,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":17930,"kind":"person","name":"Kalofonos Isabel","position":1,"cik":"0001975163","reported_name":"Kalofonos Isabel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & CHIEF COMMERCIAL OFFICER"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-02T16:32:00.000Z","date":"2023-04-28","kind":"grant","planned":false,"acquired":true,"shares":284250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These options vest over a four-year period, with 25% of the shares vesting on the one-year anniversary of the date of grant, and thereafter an additional 6.25% of the shares vesting on each succeeding quarterly anniversary of the date of grant, subject to continued service through each vesting date."}],"balance_after":284250,"derivative":{"exercise_price":5.39,"expiration_date":"2033-04-28","underlying":"Common Stock","underlying_shares":284250},"source":{"system":"sec-edgar","filing":"0001415889-23-007094","document":"form4-05022023_080554.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/855654/000141588923007094/form4-05022023_080554.xml","form_type":"4"}}]}